STAAR Surgical (NASDAQ:STAA) Posts Earnings Results, Beats Expectations By $0.07 EPS

STAAR Surgical (NASDAQ:STAA) announced its quarterly earnings data on Wednesday. The medical instruments supplier reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.07, FiscalAI reports. STAAR Surgical had a negative net margin of 7.24% and a positive return on equity of 3.33%. The company had revenue of $93.52 million during the quarter, compared to analysts’ expectations of $78.72 million. During the same quarter in the prior year, the company earned ($1.10) EPS. The firm’s revenue was up 119.6% on a year-over-year basis.

Here are the key takeaways from STAAR Surgical’s conference call:

• STAAR reported a strong Q1 2026 with net sales of $93.5 million, up 119.6% year over year, and adjusted EBITDA swung to a $24.4 million profit from a $26.3 million loss last year.
• China drove the quarter, with $47.4 million in sales, early demand for EVO+ ICL, and distributor inventory back within targeted levels, which management said makes the quarter a cleaner base going forward.
• The company said it is seeing operating leverage and margin improvement, with gross margin rising to 73.6% and operating expenses down 18% excluding special items, while still targeting $225 million in full-year 2026 spending.
• STAAR highlighted several growth catalysts, including FDA approval expanding EVO ICL to patients ages 45 to 60, continued U.S. momentum with sales above $6 million, and the global milestone of more than 4 million ICLs sold.
• Management remained cautious on guidance, declining to endorse consensus or give specific Q2/Q3 forecasts because of macro, geopolitical, and seasonal uncertainty, even though it said Q2 appears to be shaping up normally.

STAAR Surgical Stock Up 8.9%

Shares of STAA opened at $32.01 on Friday. The stock has a market capitalization of $1.59 billion, a P/E ratio of -74.44 and a beta of 1.20. The firm has a fifty day simple moving average of $22.48 and a two-hundred day simple moving average of $22.58. STAAR Surgical has a twelve month low of $15.59 and a twelve month high of $35.87.

Insiders Place Their Bets

In other news, Director Broadwood Partners, L.P. purchased 316,017 shares of the company’s stock in a transaction on Friday, March 13th. The stock was acquired at an average price of $18.61 per share, with a total value of $5,881,076.37. Following the transaction, the director directly owned 16,123,842 shares of the company’s stock, valued at approximately $300,064,699.62. This represents a 2.00% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have acquired 670,213 shares of company stock worth $12,266,249. Corporate insiders own 39.90% of the company’s stock.

Institutional Investors Weigh In On STAAR Surgical

Institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in STAAR Surgical by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,390 shares of the medical instruments supplier’s stock worth $518,000 after purchasing an additional 1,267 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in STAAR Surgical by 33.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 544,843 shares of the medical instruments supplier’s stock worth $9,606,000 after purchasing an additional 136,390 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in STAAR Surgical by 11.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 123,347 shares of the medical instruments supplier’s stock worth $2,175,000 after purchasing an additional 12,841 shares in the last quarter. Creative Planning raised its holdings in STAAR Surgical by 19.9% in the 2nd quarter. Creative Planning now owns 15,695 shares of the medical instruments supplier’s stock worth $263,000 after purchasing an additional 2,606 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in STAAR Surgical by 183.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 153,371 shares of the medical instruments supplier’s stock worth $2,574,000 after purchasing an additional 99,218 shares in the last quarter. Hedge funds and other institutional investors own 96.70% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on STAA. Stifel Nicolaus upped their price objective on shares of STAAR Surgical from $18.00 to $31.00 and gave the company a “hold” rating in a research note on Thursday. Mizuho upped their price objective on shares of STAAR Surgical from $22.00 to $27.00 and gave the company a “neutral” rating in a research note on Thursday. Wells Fargo & Company cut their price objective on shares of STAAR Surgical from $30.75 to $16.00 and set an “equal weight” rating for the company in a research note on Thursday, March 5th. Wedbush raised shares of STAAR Surgical from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $26.00 to $40.00 in a research note on Thursday. Finally, Jefferies Financial Group dropped their price target on shares of STAAR Surgical from $28.00 to $21.50 and set a “buy” rating for the company in a research report on Wednesday, January 28th. Three equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $26.69.

STAAR Surgical News Summary

Here are the key news stories impacting STAAR Surgical this week:

• Positive Sentiment: STAAR Surgical reported Q1 EPS of $0.10 versus estimates of $0.03 and revenue of $93.5 million versus expectations of $78.7 million, marking a sharp improvement from a loss a year ago. STAAR Surgical earnings report
• Positive Sentiment: The company said quarterly sales hit a record level, with China momentum, cost discipline, and stabilized inventory supporting the turnaround narrative. STAAR Surgical earnings call highlights
• Positive Sentiment: Wedbush upgraded STAAR Surgical to Outperform and raised its price target to $40, citing improving China recovery prospects. Wedbush upgrade article
• Positive Sentiment: Mizuho also raised its price target on STAAR Surgical, reflecting a more constructive view on the stock after the earnings beat. Mizuho forecast article
• Neutral Sentiment: One analyst maintained a Hold/neutral view, noting that visibility into the 2026 outlook remains limited despite stable near-term trends. Needham hold rating article
• Negative Sentiment: STAAR Surgical disclosed a new regulation-related risk, adding some uncertainty around future performance and valuation. New risk disclosure article

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.